MetaVia has presented data showing its obesity therapies could offer broader benefits than weight loss alone. 

DA-1726, a novel dual agonist targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), reduced body weight by 9.1% at Day 54 in a Phase I trial, as well as reducing waist circumference by 9.8cm and BMI by 3.4 kg/m², also at Day 54. 

Elsewhere, a preclinical study evaluating vanoglipel (DA-1241), a novel G-protein-coupled receptor 119 (GPR119) agonist, found its combination with resmetirom demonstrated weight-loss effects in a mouse model.  

While monotherapies had no significant effect on body weight, combination treatment achieved a 23.6% reduction versus control, with endpoint fat mass and epididymal fat weight reduced by 43.5% and 42.1%, respectively. 

The data was presented by MetaVia at the American Diabetes Association’s (ADA) 2026 Scientific Sessions, held 5 – 8 June in New Orleans, Louisiana. 

“The late-breaking ADA 2026 data further reinforces the differentiated and complementary potential of our cardiometabolic pipeline,” said Hyung Heon Kim, President and Chief Executive Officer of MetaVia.  

“DA-1726 demonstrated clinically meaningful and progressive weight loss up to 9.1% at the 48 mg dose level without evidence of plateau, along with consistent reductions in waist circumference and BMI in a once-weekly regimen without titration.  

“Importantly, the data also demonstrates a sustained and progressive metabolic effect through Day 54, supporting continued advancement of higher-dose evaluation in our ongoing Phase I Part 3 titration studies designed to assess higher-dose exposure and durability of metabolic response, with results expected in the fourth quarter of 2026. 

“In parallel, preclinical vanoglipel combination data demonstrated synergistic effects across liver and metabolic disease models, including meaningful improvements in hepatic steatosis, liver injury markers, fibrosis-related biomarkers, glycaemic control, and body weight.” 

Kim later added the findings “support DA-1726 as a differentiated obesity therapy and vanoglipel as a versatile metabolic backbone for combination approaches in MASH (metabolic dysfunction-associated steatohepatitis) and type 2 diabetes.”